Slide background

redefining cell culture in life science

Slide background

enabling the growth of any human cell in vitro

Slide background

biologically relevant disease models for cutting edge research

enabling human biology in vitro

denovoMATRIX offers modular biomimetic matrices that can be tailored to recreate a large variety of extracellular matrices for any cell type.
easy to use

easy to use

Unpack. Seed cells. Get results.
modular

modular

Tailored environment for each cell type.
biologically relevant

biologically relevant

Meaningful results to boost research.
chemically defined

chemically defined

No batch-to-batch variation.
GxP-certifiable

GxP-certifiable

Translate research to clinics.

we are denovoMATRIX

the team

Dejan HUŠMAN
Dejan HUŠMANBioengineer, M.Sc. in Bioengineering
biomaterial engineer
Alvin THOMAS
Alvin THOMASPharmacist, Ph.D. in Chemistry
quality control scientist
Richard WETZEL
Richard WETZELBioengineer, Ph.D. in Biology
cell biology specialist
Nadine SCHMIEDER-GALFE
Nadine SCHMIEDER-GALFEBiotechnologist, MBA in Economics & Law
business developer

advisors

Robert WIEDUWILD
Robert WIEDUWILDBiologist, Ph.D. in Chemistry
Prof. Yixin ZHANG
Prof. Yixin ZHANGChemist, Ph.D. in Chemistry
Dragan GRABULOVSKI
Dragan GRABULOVSKIPharmacist, Ph.D., Co-founder Covagen

our products

mymatrix.jpg

myMATRIX.
The best substrate for your cell culture.

The myMATRIX is a unique biomimetic coating, tailored to your specific application. The myMATRIX is a distinct combination of sulfated polysaccharides and biomimetic peptides, to get you the results you need.
available from May 2018

screenMATRIX.
Discover the ideal microenvironment for your application.

The screenMATRIX is the fastest way to test a large variety of factors for isolating, maintaining or differentiating your cells. screenMATRIX consists of a cell culture plate containing a different microenvironment in each cell.
available from April 2018

screenmatrix.jpg
services.jpg

Consulting services.
Let us do the heavy lifting.

We develop, characterize and manufacture extracellular matrix-mimetic coatings for all of your cell culture needs.
get in touch with us

discover YOUR cell culture solution

applications

stem cell research

stem cell research

We provide coatings tailored for pluripotency maintenance, proliferation, patterning or differentiation.

drug development

drug development

Our fully synthetic and chemically characterized coatings enable robust culture of various cell types commonly used in drug development.

tissue models

tissue models

A variety of tissue models can be recreated on our coatings, providing advantages in  model maintainance time, clarity of results and repeatable outcomes.

diagnostics

diagnostics

Our modular matrices are currently developed for use as selective expansion of cancer stem cells from heterogenous tissue extracts, with possible applications as diagnostic tools.

cell based therapies

cell based therapies

FDA approved compounds in our coatings enable their use as cell expansion platforms.

coating medical devices

coating medical devices

A challenging aspect of the application of internal medical devices is the biological interface with the body. Our chemically defined matrices permit the incorporation of bioactive compounds, and of tuning biological responses .

biomatrices created de novo for each cell type

cell types

primary cells

human HUVECs

human HUVECs

mouse hepatocytes

mouse hepatocytes

cardiomyocytes

cardiomyocytes

stem cells

mouse neuronal precursor cells

mouse neuronal precursor cells

human iPS derived neurons

human iPS derived neurons

retinal pigmented epithelial

retinal pigmented epithelial

human MSCs

human MSCs

cancer cell lines

DU-145

DU-145

Hep G2

Hep G2

HeLa

HeLa

gliobastoma multiforme

gliobastoma multiforme

immortalized cell lines

HDFn

HDFn

renal proximal tubulus epithelial cells

renal proximal tubulus epithelial cells

blood outgrowth endothelial cells

blood outgrowth endothelial cells

we mimic the cell microenvironment that determines cell fate and function

publications

Minimal Peptide Motif for Non-covalent Peptide-Heparin Hydrogels
Characterization of a cell compatible non-covalent peptide heparin hydrogel
J Am Chem Soc. 2013;135:2919–2922.

A Repertoire of Peptide Tags for Controlled Drug Release from Injectable Noncovalent Hydrogel
Noncovalent Hydrogel Beads as Microcarriers for Cell Culture
In Vivo Examination of an Injectable Hydrogel System Crosslinked by Peptide-Oligosaccharide Interaction in Immunocompetent Nude Mice

news

ecp-logo.png
16 January 2018
2ND EUROPEAN CHEMISTRY PARTNERING, FEBRUARY 23RD 2018

We are excited to attend this year's European Chemistry Partnering Event in Frankfurt. Come see our pitch or come meet us for a discussion, we look forward to see you there!
fight-night-jena-2017.jpg
8 December 2017
Q4 2017 UPDATE

November has been an intensive - and successful - month for us! Attending both the Bio-Europe at the beginning of the month as well as the Biofit in Strasbourg last week, we could connect to new important partners around the world. Moreover, the lab team made huge steps in product development that will allow our first product roll-out in the coming year.

And finally, we attended the Technology Fight Night in Jena (see pic), and missed our on the winner's podium with only very view points! Bad luck, but we learned a lot on that day, thanks Merle Fuchs!

Right now, we are finalizing the last issues for this year, and already prepare the next steps for founding the company soon. Therefore, we are looking forward to an exciting start of next year!
termis2017.jpg
30 June 2017
TERMIS BUSINESS PLAN COMPETITION 2017

We made it to the final round of the TERMIS business plan competition! Check out our video pitch below that was part of our application package to convince the jury! Thanks to all for your support, and please keep your fingers crossed: Now, we are one out of five final teams that will pitch at the TERMIS-EU 2017 Conference on 27th June in Davos, Switzerland!



UPDATE:
ON THE PODIUM! We are proud to announce that our business concept convinced the jury in Davos, and we won the 3rd prize. Thanks to all our supporters!
biotechnica17.jpg
12 May 2017
BIOTECHNICA | LABVOLUTION 2017


We will be at the Biotechnica | Labvolution this year from 16th to 18th of May. Meet us at the "Gemeinschaftsstand Forschung für die Zukunft" in hall 20, booth C66. Looking forward to meeting you in Hanover!
grabulovski.jpg
07 March 2017
A BUSINESS COACH FOR DENOVOMATRIX

We are glad to announce that Dr. Dragan Grabulovski has joined us as our business coach and will help us with identifying our best business opportunities and to reach our strategic objectives.

Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen's CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. He was a main inventor of the Fynomer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the internal and collaboration pipeline. As a member of Covagen's executive management team, Dr. Grabulovski was instrumental in Covagen's trade sale to Johnson & Johnson, and in the closing of Covagen's CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master's degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH). He is a co-author of several peer-reviewed articles, reviews, book chapters, poster abstracts, patent applications and granted patents.

"I am impressed by the technology developed at Technische Universität Dresden that improves the cell microenvironment of standard cell culture assays, enabling researchers to perform cell assays that were challenging or impossible in the past and yielding better and reproducible results in general," said Dr. Dragan Grabulovski.

We had supportive and intense discussion during a fruitful meeting in Dresden last week, and we are very much looking forward to our future collaboration!
bionection2016.jpg
21 October 2016
QUICKSTART

denovoMATRIX awarded with bionection Technology Transfer Trophy for successful commercialization development

Just recently started at B-CUBE, the validation team denovoMATRIX already received their first award on Tuesday: the bionection Technology Transfer Trophy for best commercialization development over the last 12 month. The trophy was awarded during the bionection technology transfer conference by biosaxony, the biotech and medtech cluster agency of Saxony, and is endowed with 1,500 EUR and a consulting package of KPMG. Based on a patented technology that was developed in the B-CUBE lab of Yixin Zhang, denovoMATRIX develops novel in vivo-mimicking biomaterials for optimal cell culture conditions.

partners

cleansight.png
ctb.png
oncoray.png
biotec.png
crtd.png
ukdd.png

contact

+49 (0)351 4469 1538

denovoMATRIX
B CUBE - Center for Molecular Bioengineering
Technische Universität Dresden

Arnoldstr. 18
01307 Dresden
GERMANY

follow us